Unraveling the Mode of Action of the Antimalarial Choline Analog G25 inPlasmodium falciparumandSaccharomyces cerevisiae

Authors:

Abstract
Pharmacological studies have indicated that the choline analog G25 is a potent inhibitor ofPlasmodium falciparumgrowth in vitro and in vivo. Although choline transport has been suggested to be the target of G25, the exact mode of action of this compound is not known. Here we show that, similar to its effects onP. falciparum, G25 prevents choline entry intoSaccharomyces cerevisiaecells and inhibitsS. cerevisiaegrowth. However, we show that the uptake of this compound is not mediated by the choline carrier Hnm1. Anhnm1Δyeast mutant, which lacks the only choline transporter geneHNM1, was not altered in the transport of a labeled analog of this compound. Eleven yeast mutants lacking genes involved in different steps of phospholipid biosynthesis were analyzed for their sensitivity to G25. Four mutants affected in the de novo cytidyldiphosphate-choline-dependent phosphatidylcholine biosynthetic pathway and, surprisingly, a mutant strain lacking the phosphatidylserine decarboxylase-encoding genePSD1(but notPSD2) were found to be highly resistant to this compound. Based on these data forS. cerevisiae, labeling studies inP. falciparumwere performed to examine the effect of G25 on the biosynthetic pathways of the major phospholipids phosphatidylcholine and phosphatidylethanolamine. Labeling studies inP. falciparumand in vitro studies with recombinantP. falciparumphosphatidylserine decarboxylase further supported the inhibition of both the de novo phosphatidylcholine metabolic pathway and the synthesis of phosphatidylethanolamine from phosphatidylserine. Together, our data indicate that G25 specifically targets the pathways for synthesis of the two major phospholipids, phosphatidylcholine and phosphatidylethanolamine, to exert its antimalarial activity.

This publication has 50 references indexed in Scilit: